Company intelligence / Profile preview
Scandion Oncology
Copenhagen, Denmarkscandiononcology.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Completed Phase I/II CORIST trial for colorectal cancer with SCO-101 in combination with FOLFIRI, establishing 250mg as the recommended Phase II dose. Also completed Phase Ib PANTAX trial for pancreatic cancer showing good safety profile and promising efficacy data with progression-free survival of 2.5 months and overall survival of 9.5 months.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Scandion Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scandion Oncology.